Wilsey Jared T, Block Julie H
Medtronic Spine Division, Memphis, TN, USA.
J Pain Res. 2018 Apr 9;11:693-701. doi: 10.2147/JPR.S157018. eCollection 2018.
Previous research suggests that the α adrenergic agonist clonidine, a centrally acting analgesic and antihypertensive, may also have direct effects on peripheral pain generators. However, aqueous injections are limited by rapid systemic absorption leading to off target effects and a brief analgesic duration of action.
The aim of this study was to examine the efficacy of a sustained-release clonidine depot, placed in the wound bed, in a pig incisional pain model.
The depot was a 15 mm ×5 mm ×0.3 mm poly(lactide-co-caprolactone) polymer film containing 3% (w/w) clonidine HCl (MDT3). Fifty-two young adult mix Landrace pigs (9-11 kg) were divided into seven groups. All subjects received a 6 cm, full-thickness, linear incision into the left lateral flank. Group 1 served as a Sham control group (Sham, n=8). Group 2 received three placebo strips (PBO, n=8), placed end-to-end in the subcutaneous wound bed before wound closure. Group 3 received one MDT3 and two PBO (n=8), Group 4 received two MDT3 and one PBO (n=8), and Group 5 received three MDT3 (n=8). Positive control groups received peri-incisional injections of bupivacaine solution (Group 6, 30 mg/day bupivacaine, n=8) or clonidine solution (Group 7, 225 µg/day, n=4).
The surgical procedure was associated with significant peri-incisional tactile allodynia. There was a dose-dependent effect of MDT3 in partially reversing the peri-incisional tactile allodynia, with maximum pain relief relative to Sham at 72 hours. Daily injections of bupivacaine (30 mg), but not clonidine (up to 225 µg), completely reversed allodynia within 48 hours. There was a statistically significant correlation between the dose of MDT3 and cumulative withdrawal threshold from 4 hours through the conclusion of the study on day 7.
These data suggest that a sustained-release clonidine depot may be a viable nonopioid, nonamide anesthetic therapy for the treatment of acute postsurgical nociceptive sensitization.
先前的研究表明,α肾上腺素能激动剂可乐定,一种中枢性镇痛药和抗高血压药,可能也对外周疼痛源有直接作用。然而,水剂注射因全身快速吸收而受限,导致产生非靶向效应且镇痛作用持续时间短暂。
本研究旨在检验置于伤口床的缓释可乐定储库在猪切口疼痛模型中的疗效。
该储库是一种15毫米×5毫米×0.3毫米的聚(丙交酯-共-己内酯)聚合物薄膜,含有3%(重量/重量)的盐酸可乐定(MDT3)。52只年轻成年杂交长白猪(9 - 11千克)被分为七组。所有受试者在左侧胁腹处接受一个6厘米的全层线性切口。第1组作为假手术对照组(假手术组,n = 8)。第2组在伤口闭合前,将三条安慰剂条带(PBO,n = 8)首尾相连置于皮下伤口床。第3组接受一条MDT3和两条PBO(n = 8),第4组接受两条MDT3和一条PBO(n = 8),第5组接受三条MDT3(n = 8)。阳性对照组在切口周围注射布比卡因溶液(第6组,30毫克/天布比卡因,n = 8)或可乐定溶液(第7组,225微克/天,n = 4)。
手术操作与切口周围显著的触觉异常性疼痛相关。MDT3在部分逆转切口周围触觉异常性疼痛方面存在剂量依赖性效应,在72小时时相对于假手术组疼痛缓解最大。每日注射布比卡因(30毫克)可在48小时内完全逆转异常性疼痛,但注射可乐定(高达225微克)则不能。从4小时到研究第7天结束,MDT3的剂量与累积撤药阈值之间存在统计学上的显著相关性。
这些数据表明,缓释可乐定储库可能是一种可行的非阿片类、非酰胺类麻醉疗法,用于治疗急性术后伤害性感受敏化。